Inhibition of the PI3K/AKT pathway leads to decreased cell proliferation in chronic lymphoblastic leukemia (CLL) [13] and acute myeloid leukemia (AML) [14,15]. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.